"Subscription | Strategic review identifies efficiencies The Subscription business continues to be profitable, however as a result of major regulatory headwinds and the maturity of the Subscription model, it is expected to report a 27% decline FY17 vs FY18 revenue to $13.8m and a 36% decline H1 FY18 vs H2 FY18 (from $8.4m at H1 FY18 to $5.4m in H2 FY18)"
:-(
- Forums
- ASX - By Stock
- UNT
- Ann: FY18 Update
Ann: FY18 Update, page-4
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
Add UNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.66M |
Open | High | Low | Value | Volume |
1.6¢ | 1.7¢ | 1.6¢ | $31.70K | 1.956M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 299999 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 225583 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 299999 | 0.016 |
14 | 2451999 | 0.015 |
7 | 2165510 | 0.014 |
7 | 3274277 | 0.013 |
5 | 2441750 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 57719 | 2 |
0.018 | 720000 | 3 |
0.019 | 1520000 | 5 |
0.020 | 1104579 | 4 |
0.021 | 1804688 | 8 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
UNT (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online